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Study Objectives. To identify the types and frequencies of adverse events
associated with community-based amphotericin B infusion therapy.  A
second objective was to validate the effectiveness of a monitoring system,
based on guidelines from the Infectious Diseases Society of America
(IDSA).
Design. Retrospective medical record review.
Setting. Outpatient clinic at a tertiary care center.
Patients. One hundred five patients who received amphotericin B therapy
from a home care provider between January 1997 and July 2002.
Measurements and Main Results A total of 113 courses of amphotericin B
formulations were administered:  liposomal amphotericin B, 41 courses
(36%), amphotericin B deoxycholate, 31 courses (27%), amphotericin B
lipid complex, 31 courses (27%), and amphotericin B colloidal dispersion,
3 courses (3%); an additional 7 courses consisted of sequential therapy
with two different formulations.  Nephrotoxicity was associated with 46
(41%) courses, electrolyte abnormalities with 40 (35%) courses, venous
access device complications with 12 (11%) courses, and infusion reactions
with 13 (12%) courses.  Nephrotoxicity occurred most frequently in adults
aged 60 years or older, solid organ transplant recipients, and those
receiving concomitant cyclosporine.  Only two (12%) of 17 courses in
children younger than 13 years were associated with nephrotoxicity.
Thirteen of all 113 courses resulted in patients requiring hospital admission
due to their adverse events.  Monitoring of electrolyte, serum creatinine,
and blood urea nitrogen levels 2 or 3 times/week was adequate for
identifying these events.
Conclusion. Significant rates of adverse events occurred in patients who
received community-based amphotericin B infusion therapy.  A monitoring
system based on IDSA guidelines was effective in facilitating the detection
and management of these adverse events.
Key Words: amphotericin B, community-based therapy, adverse effects,
nephrotoxicity, monitoring.
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Community-based antiinfective therapy has
enjoyed increasing popularity during the past 2
decades.  Today, with sufficient support and
education, antimicrobials can be administered
safely and cost-effectively in the home setting.1–6
However, adverse events related to outpatient
antimicrobial infusion can have a significant
impact on patient health.2, 7, 8 Bone marrow
suppression, diarrhea, rash, nephrotoxicity, and
catheter-related complications were among the
adverse events identified during a 2-year period
in 261 patients receiving community-based
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antiinfective therapy.7 Of 10 patients who
received amphotericin B (AmB), seven developed
renal failure.  A retrospective study of thrombotic
complications with peripherally inserted central
catheters identified AmB therapy as a significant
independent risk factor for development of this
complication.8
Adverse events related to inpatient use of AmB
are well established and include infusion-related
toxicities, renal failure, and electrolyte abnor-
malities.9–11 Today, an increasing number of
patients are receiving extended courses of
antifungal therapy, including AmB.  Previous
studies have not specifically addressed the safety
of infusing AmB in the outpatient setting.  We
sought to identify the types and frequencies of
adverse events associated with this form of
therapy and the appropriateness of our
monitoring system, based on guidelines from the
Infectious Diseases Society of America.6
Methods
Setting and Patients
The University of Michigan Health System
(UMHS) is an 850-bed tertiary care center.  Our
study population included all adult and pediatric
outpatients who received any formulation of
AmB between January 1997 and July 2002
through HomeMed, a UMHS Joint Commission
on Accreditation of Healthcare Organizations–
accredited home care provider.  Working in
conjunction with the referring physician,
HomeMed clinical pharmacists and nursing staff
start infusion therapy, order relevant laboratory
tests, and fill prescriptions for infusion products
and home care supplies.  HomeMed staff
members are responsible for providing patient
education, drug information, and compliance
assessment, as well as assisting with management
of infusion-related complications.  Study patients
were identified using a computerized database
maintained by HomeMed.  The study was
approved by the institutional review boards of
both the University of Michigan Health System
and the Veterans Affairs Ann Arbor Healthcare
System.
All patients included in the study were
followed in UMHS clinics during the period in
which they received AmB home infusion.  All
patients had a long-term venous access device,
either a peripherally inserted central catheter line
or a surgically placed device, such as a Hickman
catheter or an infusion port.  Laboratory studies
were monitored a minimum of twice/week.
Amphotericin B Formulations
The formulations of AmB prescribed were
amphotericin B deoxycholate (AmBd), ampho-
tericin B colloidal dispersion (ABCD), ampho-
tericin B lipid complex (ABLC), and liposomal
amphotericin B (L-AmB).
Study Design and Data Collection
For each patient, the medical chart, HomeMed
record, pharmacy dispensing information, and
microbiology data were reviewed.  Information
collected included demographic data, underlying
medical conditions, concomitant drugs, and
frequency of patient visits and laboratory testing.
Indications for antifungal therapy were
categorized as definite, probable, or possible
invasive fungal infection (in accordance with the
European Organization for Research and
Treatment of Cancer–Mycoses Study Group
criteria),12 empiric, or prophylactic.  The AmB
formulation, dosage, duration of therapy, and
occurrence of adverse events during treatment
were recorded.  Hospital admissions were
documented, along with a determination of
whether these were a direct result of compli-
cations of AmB infusion.
Definitions of Adverse Events
Nephrotoxicity was defined as an increase in
serum creatinine level of at least 1 mg/dl or a
doubling of serum creatinine level compared
with the baseline value on day 1 of AmB therapy.
Electrolyte imbalance was defined as hypo-
kalemia (serum potassium level < 3.5 mEq/L) or
hypomagnesemia (serum magnesium level < 1.5
mEq/L) occurring during the course of outpatient
therapy with AmB.  Infusion reactions were
chills, fever, nausea, vomiting, dyspnea, chest
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pain, hypotension, and muscle spasm occurring
during or immediately after AmB infusion.
Venous access device complications consisted of
deep vein thrombosis, accidental removal of a
device, pump malfunction, leaking, and infection.
Statistical Analysis
The x2 test was used to compare dichotomous
variables, and the Student t test was used to
compare continuous variables.  A p value of less
than 0.05 was considered to indicate a statis-
tically significant difference.
Results
Patient Characteristics
A total of 105 evaluable patients received 113
courses of AmB through HomeMed Services from
January 1997–July 2002.  The mean ± SD age was
40.5 ± 21.8 years (range 2 mo–82 yrs); 63 (60%)
were males.  Fifteen (14%) of the patients who
received 17 courses were younger than 13 years
of age, including seven infants who were 1 year
old or younger.  Twenty-two (21%) of the
patients who received 24 courses were 60 years
of age or older. Most patients had two or more
underlying medical conditions (Table 1).  The
most common underlying conditions were
hematologic malignancy, neutropenia, and stem
cell transplantation.  As shown in Table 2,
indications for therapy were definite or probable
invasive fungal infection (55 [49%] courses [one
patient had two simultaneous infections]),
possible invasive fungal infection (32 [28%]
courses), empiric therapy (13 [12%] courses),
and prophylaxis (13 [12%] courses).
Amphotericin B Therapy
The most frequently administered AmB
preparation was L-AmB, which was given as the
sole AmB preparation for 41 (36%) courses.  It
was followed by AmBd and ABLC, which were
each the sole AmB preparation in 31 (27%)
courses.  In three (3%) courses, ABCD was the
sole AmB preparation (Table 3).  Sixteen patients
received two AmB formulations sequentially
during their course of therapy.  However, nine of
the 16 patients received AmBd for less than 3
days before switching to a lipid formulation;
adverse events in these patients were ascribed to
the lipid formulation, which constituted almost
all of their therapy.  The remaining seven of the
16 patients received AmBd for at least 4 days
(range 4–44 days) before being given a lipid
formulation.  These patients were considered to
have been treated with both drugs for purposes
of analysis of adverse events.
The mean ± SD duration of outpatient AmB
therapy was 33 ± 37 days (range 1–257 days).
For ABLC, the mean duration was 38 ± 31 days
versus 31 ± 30 days for L-AmB, 31 ± 49 days for
AmBd, and 17 ± 14 days for ABCD.  The mean
duration of earlier inpatient AmB therapy was 10
± 9 days for AmBd, 12 ± 15 days for ABLC, 13 ±
13 days for L-AmB, and 10 ± 10 days for ABCD.
Infusion times were targeted for 3 hours for
AmBd and ABCD, and 2 hours each for ABLC
and L-AmB.  Mean daily doses were AmBd 0.7 ±
0.3 mg/kg, ABLC 4.5 ± 0.9 mg/kg, L-AmB 4 ± 1
mg/kg, and ABCD 4 ± 1 mg/kg.
The number of patients receiving community-
based AmB therapy increased over the study
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Table 1.  Underlying Conditions Among 105 Patients Who
Received 113 Courses of Home Infusion Therapy with
Amphotericin B
No. (%)
Conditiona of Patients
Hematologic malignancy 51 (49)
Neutropenia (< 500 cells/mm3) 51 (49)
Allogeneic stem cell transplant 28 (27)
Solid organ transplant 22 (21)
Renal insufficiencyb 22 (21)
Graft vs host disease 16 (15)
Diabetes mellitus 11 (11)
Hemodialysis 6 (6)
Solid tumor 5 (5)
Autologous stem cell transplant 3 (3)
Cirrhosis 3 (3)
Acquired immunodeficiency syndrome 1 (1)
aMost patients had more than one condition.
bFor adults, defined as a serum creatinine level of 2 mg/dl or
greater; for children, defined as less than 50% of the normal value
for each child’s age group.
Table 2.  Indications for Home Infusion Therapy with
Amphotericin B in 105 Patients Who Received 113
Courses
No. (%)
Indication of Coursesa
Definite or probable fungal infection
Candidiasis 25 (22)
Aspergillosis 23 (20)
Other filamentous fungib 5 (4)
Histoplasmosis or coccidioidomycosis 3 (3)
Possible fungal infection 32 (28)
Empiric therapy 13 (12)
Prophylaxis 13 (12)
aOne patient had both candidiasis and aspergillosis.
bIncludes zygomycoses (two courses), Fusarium (two courses), and
Scedosporium (one course).
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period.  In the second half of the study, a larger
proportion of patients started therapy with a lipid
formulation.  Only 5 (50%) of 10 courses began
with a lipid formulation in 1997, compared with
42 (81%) of 52 courses from January 2001–July
2002.  The seven patients who had received
AmBd for at least 4 days before being given a
lipid formulation were evenly distributed from
1997–2002.  Laboratory values were monitored
twice/week for 66 (58%) courses and 3 times/week
for 47 (42%) courses.
Adverse Events
The overall rate of adverse events was 72% (81
of 113 courses).  Nephrotoxicity was associated
with 46 (41%) courses of AmB therapy.  In these
patients, mean ± SD baseline serum creatinine
level was 1.0 ± 0.5 mg/dl, which increased to a
mean peak of 2.4 ± 0.7 mg/dl.  The mean ± SD
number of days of therapy before development of
nephrotoxicity was 25 ± 25 (range 4–105).  The
overall rate of nephrotoxicity in the outpatient
setting did not differ between patients receiving
standard AmB versus lipid formulations (Table
3).  The lowest rate of nephrotoxicity (32%) was
noted with L-AmB (13 of 41 courses), but this
was not statistically different from that noted
with ABLC (14 [45%] of 31 courses, p=0.36) or
with AmBd (12 [39%] of 31 courses, p=0.71).
When children younger than 13 years are
excluded from the analysis, the rate of nephro-
toxicity with AmBd increases to 50%.
Sodium loading with normal saline before
infusion of AmB was ordered on day 1 and
continued throughout outpatient AmB treatment
for 43 (38%) of 113 courses.  Sodium loading
was performed in approximately one half of the
courses in which AmBd or L-AmB were used, but
only in 34% of courses of ABLC.  Thirteen (30%)
of the 43 courses in which sodium loading was
prescribed were associated with nephrotoxicity,
compared with 33 (47%) of the 70 courses in
which sodium loading was not prescribed
(p=0.11).
During 40 (35%) of the 113 courses of therapy,
hypokalemia and/or hypomagnesemia developed.
Electrolyte abnormalities occurred irrespective of
the AmB formulation used (Table 3).  Further-
more, electrolyte abnormalities persisted despite
aggressive oral supplementation in 27 (24%)
courses of therapy, and two patients required
hospitalization for intravenous potassium supple-
mentation.
We also compared the various AmB formu-
lations with regard to the time until nephro-
toxicity or electrolyte disturbances were recorded.
Similar intervals were noted with AmBd (18 ± 19
days) and ABLC (19 ± 19 days).  The interval was
shortest for the few patients receiving ABCD (14
± 8 days).  The longest interval until nephro-
toxicity or electrolyte distur-bances occurred was
noted with L-AmB (23 ± 19 days); however, this
interval was not significantly different compared
with ABLC (p=0.43) or AmBd (p=0.39).
In patients aged 60 years or older, 16 (67%) of
24 AmB courses were associated with nephro-
toxicity, and 13 (54%) with electrolyte abnor-
malities.  Nephrotoxicity was associated wih
seven (78%) of nine ABLC courses, five (56%) of
nine L-AmB courses, two (50%) of four AmBd
courses, and in one course each of ABCD or
AmBd followed by a lipid formulation.  Only
eight courses of AmB in older adults were
preceded with sodium loading.  Nephrotoxicity
occurred in four (50%) of eight patients in this
group versus 12 (75%) of the 16 patients not
given sodium loading (p=0.44).
Among 17 courses of AmB given in children
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Table 3.  Nephrotoxicity and Electrolyte Abnormalities Related to Different
Amphotericin B Formulations in 105 Patients Who Received 113 Courses of
Therapy
No. of No. (%) of Courses
Formulation Courses Nephrotoxicity Electrolyte Imbalance
AmBd 31 12 (39) 11 (36)
AmBd + lipida 7 4 (57) 4 (57)
ABLC 31 14 (45) 12 (39)
L-AmB 41 13 (32) 13 (32)
ABCD 3 3 (100) 0
AmBd = amphotericin B deoxycholate; ABLC = amphotericin B lipid complex; L-AmB =
liposomal amphotericin B; ABCD = amphotericin B colloidal dispersion.
aThese seven patients received AmBd for at least 4 days before treatment with ABLC (four
patients) or L-AmB (three patients).
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younger than 13 years old, nine were with AmBd.
Only one (11%) course of AmBd was associated
with nephrotoxicity, and two courses were
associated with electrolyte abnormalities.  In
children treated with lipid formulations (eight
courses), one course was associated with
nephrotoxicity and three courses were associated
with electrolyte abnormalities.  Sodium loading
was prescribed in eight of all 17 courses
administered to children.  Overall, nephrotoxicity
occurred in only 12% of courses of AmB given to
children younger than 13 years of age.
Nephrotoxicity was significantly lower in this
population (12%) than in patients aged 60 years
or older (67%) (p=0.002).
Twenty-four AmB courses were given to 22
solid organ transplant recipients.  In this group,
there were 14 lung, four liver, three kidney, and
one heart transplants.  The mean ± SD age of the
recipients was 52 ± 10 years.  The AmB
formulations were ABLC (11 [46%] courses), L-
AmB (six [25%] courses), AmBd (three courses),
ABCD (three courses), and AmBd followed by a
lipid formulation (one course).  Of the 24
courses of AmB therapy, 21 were given to patients
receiving cyclosporine and three to patients
receiving tacrolimus.  Nephrotoxicity developed
during 15 (63%) of the 24 courses, and eight
(33%) courses were accompanied by electrolyte
abnormalities.
Thirty-three courses of therapy with AmB were
given to 31 stem cell transplant recipients.
Twenty-two of these patients also received
tacrolimus, and one was given cyclosporine.  The
mean ± SD age of this group was 34 ± 19 years.
The preferred formulation in this population was
L-AmB, which was given for 22 (67%) of 33
courses.  Other formulations used were ABLC
(five courses), AmBd (five courses), and AmBd
followed by ABLC (one course).  Only eight
(24%) of AmB courses in stem cell transplant
recipients were associated with nephrotoxicity;
similarly, eight courses were associated with
electrolyte abnormalities.
In the total transplant population, those
receiving ABLC had more nephrotoxicity (eight
[47%] of 17 courses) than those receiving L-AmB
(eight [29%] of 28 courses).  Courses given with
concomitant cyclosporine were associated with
greater nephrotoxicity (14 [64%] of 22 courses)
than courses given with concomitant tacrolimus
(8 [32%] of 25 courses, p=0.06)
Infusion-related events were noted during 13
(12%) courses.  Rigors or chills were noted in 11
of these courses, hypotension in one, and severe
back spasms in one.  These events were primarily
seen in patients receiving ABLC (nine patients),
followed by L-AmB (three patients), and AmBd
(one patient).  Physician responses to infusion
reactions included adding meperidine or
hydrocortisone to the regimen, slowing the
infusion rate, and switching to a different lipid
formulation of AmB.  Three patients had AmB
discontinued solely because of infusion-related
reactions that could not be controlled with
prophylactic drugs given before the AmB.
Venous access device complications were noted
in 12 (11%) courses in 11 patients.  Problems
with peripherally inserted central catheter lines
consisted of inadvertent removal (four courses),
purulence at the exit site (two courses), improper
insertion (one course), and leakage at the exit
site (one course).  One patient had a malfunc-
tioning pump device.  Two patients with periph-
erally inserted central catheter lines developed
upper-extremity deep vein thrombosis that
required anticoagulation, and another patient
developed a Staphylococcus aureus catheter-
related infection.  Two of the 11 patients had
AmB discontinued solely because of venous
access problems.
Thirteen (12%) courses in 13 patients resulted
in hospital admission due to their AmB-related
adverse events.  Reasons for hospitalization were
adverse events related to nephrotoxicity (seven
patients), venous access device complications
(catheter infection, deep vein thrombosis,
peripherally inserted central catheter placement;
four patients), and correction of electrolyte
abnormalities (two patients).
Overall, 28 (25%) outpatient courses of AmB
were stopped because of adverse events.  Of the
28, 24 were associated with nephrotoxicity, but
eight were also associated with electrolyte abnor-
malities, and six involved infusion reactions.
Discussion
During the past 2 decades, the use of community-
based antimicrobial infusion has burgeoned.
With improving support networks and the growing
pressure to decrease hospital lengths of stay, an
increasing number of patients are sent home to
complete their course of antimicrobial therapy.
At the same time, the ability to treat previously
fatal conditions has resulted in large numbers of
immunocompromised patients who often require
prolonged therapy with potentially toxic agents.
Many of these agents, including AmB, are now
given in the home setting.
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We sought to determine how frequently
toxicity is associated with community-based
therapy with AmB and whether recommendations
for monitoring patients appear adequate.  To do
this, we focused on adverse events that occurred
in the outpatient, rather than the inpatient,
setting for a large number of patients receiving
AmB therapy.  It is important to note that we
included only adverse events that met our study
definitions.  Eleven courses of AmB in 11
patients resulted in toxicity before the start of
outpatient therapy; these courses were not
counted as having toxicity associated with home
AmB infusion therapy.  It is likely that some
patients experienced mild toxicity as inpatients
but did not meet our definition for toxicity.
However, as outpatients, this toxicity continued,
and they were then included in our analysis as
experiencing an adverse event during home AmB
infusion therapy.  Overall our findings demonstrate
that home infusion of AmB was associated with
adverse events related to 81 (72%) of 113 courses
of therapy.  This adverse-event rate is similar to
that noted in a small study consisting of 10
patients who received AmB at home.7
Not surprising, nephrotoxicity, occurring with
41% of the AmB courses, was the most common
adverse event.  Although the rate of nephrotoxicity
was high, this was not unexpected.  Twice-
weekly evaluation of kidney function appeared to
identify this toxicity appropriately.  A total of
seven hospital admissions were required for
symptomatic renal dysfunction, but no patient
required dialysis.  In 21% of the courses, however,
nephrotoxicity led to discontinuation of AmB.
The highest rates of nephrotoxicity were
observed in patients who were 60 years of age or
older, those who had received a solid organ
transplant, and those who were taking comcomi-
tant cyclosporine.  However, it is not clear which
of these factors played the most important role or
whether, as is most likely, a combination of all of
these factors led to nephrotoxicity.  Unfortunately,
the small sample size of patients receiving
different formulations of AmB limited our ability
to perform statistical analyses that would help
determine causality. An age-related increase in
AmB-associated nephrotoxicity seems intuitive,
but this has not been noted as a major factor in
several studies that looked at risk factors for
AmB-associated nephrotoxicity in hospitalized
patients.13–16
One review article reported a high rate of AmB-
induced nephrotoxicity among transplant
recipients.13 That review differs from our study
in that nephrotoxicity was higher in patients who
received stem cell transplants than in those who
received solid organ transplants.  The predominant
use of tacrolimus rather than cyclosporine in our
stem cell transplant recipients may have helped
obviate nephrotoxicity; the concomitant use of
cyclosporine and AmB has been shown to be
highly predictive of the subsequent need for
hemodialysis in stem cell transplant recipients.13
In our study, lipid formulations of AmB did not
appear to protect against nephrotoxicity.  These
results differ from those noted in hospitalized
patients.17–20 However, several characteristics of
our study help explain the lack of differences in
nephrotoxicity found among the various AmB
formulations.  First, nearly 30% of the AmBd
courses were given to children, and children are
known to experience fewer toxicities from AmB
than adults; this decreased the nephrotoxicity
rate in the AmBd group below that usually
noted.13, 15, 18 In fact, if children are removed
from that group, the rate of nephrotoxicity
becomes 50%, which is higher than that noted
with ABLC or L-AmB.
Second, it is likely that patients deemed to be
at higher risk for nephrotoxicity were preferentially
prescribed lipid formulations of AmB.  Thus, a
protective effect on nephrotoxicity could have
been lost, as higher risk patients were given these
formulations.  It did appear that less nephrotoxicity
occurred with L-AmB than ABLC, as previously
noted,21 but this could also be because different
patient populations, who were treated with
different calcineurin inhibitors, received these
two formulations.  Our study was not designed to
show that one formulation of AmB was less toxic
than another, but rather to assess adverse events
and determine if our method for following
patients in the home setting was adequate to
monitor for these events.  To determine differing
risks for nephrotoxicity among several AmB
formulations would require much larger numbers
of patients and control over the use of concomitant
nephrotoxic agents and adjuvant measures, such
as sodium loading.
There was a trend toward less nephrotoxicity
when sodium loading was used, but the
differences were not statistically significant.
Previous studies in hospitalized patients have
shown a beneficial effect of sodium loading with
AmBd therapy.22, 23 It is likely that sodium
loading was not as aggressively followed in the
home setting as it could be in the hospital.  No
trials have assessed the effect of sodium loading
with lipid formulations of AmB, and it is left to
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the clinician to decide whether this might be
appropriate.  Thus, in our population, sodium
loading was only prescribed for 38% of the
courses of therapy.  Others have shown that
volume loading (massive hydration) effectively
decreases AmB-associated nephrotoxicity,24 but
this practice does not lend itself to home infusion
therapy.
Therapy for hypokalemia and hypomagnesemia
was problematic in many patients.  Intravenous
potassium supplementation can sometimes be
given in the home setting, but the patient must
be carefully monitored.  Even oral potassium
supplementation can be dangerous in the setting
of fluctuating renal function.  One patient who
received oral potassium supplementation for
refractory hypokalemia and was monitored
twice/week still developed hyperkalemia when
AmB-related renal dysfunction occurred.  Serum
potassium levels in several patients were difficult
to maintain despite aggressive oral supplemen-
tation, and two patients required hospitalization
to correct hypokalemia.
Conclusion
Due to the burgeoning use of community-
based antimicrobial infusion, it is important to
consider the adverse effects of home infusion
therapy with AmB and to specify how patients
who receive this therapy should be monitored.
We found that significant rates of four types of
adverse events occurred:  nephrotoxicity was
associated with 46 (41%) of the 113 AmB
courses, electrolyte abnormalities with 40 (35%)
courses, infusion reactions with 13 (12%)
courses, and venous access device complications
with 13 (12%) courses.  The overall rate of
adverse events was 72%.
New antifungal agents, including second-
generation triazoles and echinocandins, are
redefining the role of AmB, especially for long-
term use in immunocompromised hosts.20, 25, 26
Given the high rate of adverse events and the
frequency of monitoring that is required, the
indications for the use of AmB in this community-
based setting must be weighed carefully.  Even
seemingly minor adverse events, such as infusion
reactions, pose a risk that makes AmB less
attractive now that suitable less toxic alternatives
are available.
For those patients who require long-term AmB
therapy in the outpatient setting, recommendations
call for twice-weekly monitoring of blood urea
nitrogen, serum creatinine, and potassium levels
and weekly monitoring of complete blood count
and magnesium level.  Our study corroborates
these recommendations and also leads us to
suggest that older adults should be monitored
more frequently than younger patients.  For AmB
to be safely used in the community-based setting,
it is essential to have an infrastructure in place
that can both monitor and manage the compli-
cations associated with AmB administration.
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